DT Investment Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

DT Investment Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$19.6K	Hold	44	–	–	﹤0.01%	325
2025 Q4	$19.9K	Hold	44	–	–	﹤0.01%	335
2025 Q3	$17.2K	Hold	44	–	–	﹤0.01%	350
2025 Q2	$19.6K	Hold	44	–	–	﹤0.01%	330
2025 Q1	$21.3K	Hold	44	–	–	﹤0.01%	313
2024 Q4	$17.7K	Hold	44	–	–	﹤0.01%	339
2024 Q3	$20.5K	Buy	44 +29	+193%	+$13.9K	﹤0.01%	351
2024 Q2	$7.03K	Hold	15	–	–	﹤0.01%	405
2024 Q1	$6.27K	Hold	15	–	–	﹤0.01%	369
2023 Q4	$6.69K	Hold	15	–	–	﹤0.01%	362
2023 Q3	$5.22K	Hold	15	–	–	﹤0.01%	371
2023 Q2	$5.22K	Hold	15	–	–	﹤0.01%	378
2023 Q1	$5.17K	Hold	15	–	–	﹤0.01%	376
2022 Q4	$4.33K	Hold	15	–	–	﹤0.01%	402
2022 Q3	$4K	Buy	+15	New	+$4.32K	﹤0.01%	384

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

DT Investment Partners's VRTX Position: Q1 2026 in Review

DT Investment Partners held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 44 shares worth $19.6K. The position accounts for ﹤0.01% of the portfolio, ranked #325.

DT Investment Partners first reported a position in VRTX in Q3 2022 and has held it in 15 quarters since. The position peaked at $21.3K in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

DT Investment Partners held 44 shares of Vertex Pharmaceuticals worth $19.6K as of Q1 2026.
DT Investment Partners left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
Vertex Pharmaceuticals made up ﹤0.01% of DT Investment Partners's portfolio in Q1 2026, its #325 holding.
DT Investment Partners first reported a position in Vertex Pharmaceuticals in Q3 2022 and has held it in 15 quarters since.
DT Investment Partners's Vertex Pharmaceuticals position peaked at $21.3K in Q1 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on DT Investment Partners's 13F filing for Q1 2026, filed 15 May 2026.